COMMUNIQUÉS West-GlobeNewswire

Instil Bio’s Subsidiary Discontinues Clinical Development of AXN-2510 and Terminates License and Collaboration Agreement with ImmuneOnco
06/01/2026
DALLAS, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (Nasdaq: TIL) (“Instil”) today announced that Axion Bio, Inc. (“Axion”), a wholly-owned subsidiary of Instil, has decided to discontinue clinical development of [...]
Tonix Pharmaceuticals to Present at Two Investor Conferences in January 2026
06/01/2026
BERKELEY HEIGHTS, N.J., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully integrated, commercial biotechnology company, announced today that Tonix [...]
Oruka Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
06/01/2026
MENLO PARK, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical stage biotechnology company developing novel biologics designed to set a new standard for the treatment [...]
Fischer Imaging to Present at RESI JPM 2026 Innovator’s Pitch Challenge
06/01/2026
DENVER, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Dense breast tissue, which is present in approximately half of all women, creates challenges for radiologists to detect cancer while also bringing a higher risk of developing [...]
Tilray Brands Expands Dry January Offerings with Zero-Proof Spirits, Non-Alcoholic Beers and Hemp-Derived THC Beverages
06/01/2026
NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (Nasdaq: TLRY; TSX: TLRY), a global lifestyle and consumer packaged goods company at the forefront of the beverage, cannabis and wellness industries, is [...]
Transpire Bio Announces Completion of First Human Dosing in Clinical Trial Using its Novel Inhalation Formulation
06/01/2026
SUNRISE, Fla., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Transpire Bio, an integrated clinical-stage biopharmaceutical company focused on developing inhaled therapeutics for pulmonary and systemic diseases, today announced that [...]
Seres Therapeutics Announces Publications in Nature Medicine and Journal of Infectious Diseases Highlighting Vowst™ Mechanism of Action and Supporting Broader Live Biotherapeutic Strategy
06/01/2026
Data demonstrate clinical translation of VOWST mechanisms of action in both first and multiply recurrent CDI patients Seres MbTx ® platform provides high-resolution functional biological understanding of live [...]
NovaBridge Presents Positive Givastomig Dose Expansion Data from the Phase 1b Combination Study in Patients with 1L Metastatic Gastric Cancer
06/01/2026
Givastomig, a CLDN18.2 x 4-1BB bispecific antibody, continues to show robust efficacy when combined with nivolumab and chemotherapy (mFOLFOX6) in 1L HER2-negative, metastatic gastric cancer patients, with 77% ORR [...]
BioCryst to Present at 44th Annual J.P. Morgan Healthcare Conference
06/01/2026
RESEARCH TRIANGLE PARK, N.C., Jan. 06, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the 44 th Annual J.P. Morgan Healthcare Conference in [...]
Atea Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
06/01/2026
BOSTON, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics [...]
LB Pharmaceuticals Strengthens Leadership Team with Key Appointments in Corporate Affairs and People & Culture
06/01/2026
NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals, Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a clinical-stage biopharmaceutical company developing novel therapies for schizophrenia, [...]
NMD Pharma to present at the 44th Annual J.P. Morgan Healthcare Conference
06/01/2026
Aarhus, Denmark, 6 January 2026 – NMD Pharma A/S, a clinical-stage biotech company dedicated to developing novel and improved treatments for patients living with neuromuscular diseases, today announces that Thomas Holm [...]
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06/01/2026
RESEARCH TRIANGLE PARK, N.C., Jan. 06, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted one newly-hired [...]
MindRank Initiates Phase III "MOBILE" Trial for MDR-001: an Oral GLP-1RA Small Molecule Engineered with AI
06/01/2026
MDR-001 progressed from program discovery to Phase III in just 4.5 years, much faster than traditional development cycles. Phase IIb data demonstrated 10.3% mean weight reduction at Week 24 with a best-in-class safety [...]
SurgiBox Inc. Appoints Kelly Laurel as Chief Executive Officer
06/01/2026
Current COO to Lead First-of-its-Kind Medical Device Company into Next Phase of Global Growth and Expansion CAMBRIDGE, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- SurgiBox Inc., the medical technology company transforming [...]
Hummingbird Bioscience Announces First Patient Dosed in Phase I Clinical Trial of HMBD-501 in Advanced HER3-Expressing Solid Malignancies
06/01/2026
HMBD-501 is a HER3-targeted ADC with a differentiated mechanism of action, engineered by Hummingbird Bioscience for optimal safety and efficacy SINGAPORE, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Hummingbird Bioscience, a [...]
Oculis Announces U.S. FDA Breakthrough Therapy Designation Granted to Privosegtor for Treatment of Optic Neuritis
06/01/2026
ZUG, Switzerland, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Breakthrough Therapy Designation granted to Privosegtor, a neuroprotective candidate, for the treatment of optic neuritis Privosegtor is advancing in the [...]
Oculis Announces U.S. FDA Breakthrough Therapy Designation Granted to Privosegtor for Treatment of Optic Neuritis
06/01/2026
ZUG, Switzerland, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Breakthrough Therapy Designation granted to Privosegtor, a neuroprotective candidate, for the treatment of optic neuritis Privosegtor is advancing in the [...]
Fagron announces the completion of Purifarma
06/01/2026
Regulated information - inside information Nazareth (Belgium)/Rotterdam (The Netherlands), 6 January 2026 – 7:00 AM CET Fagron announces the completion of Purifarma Fagron, the leading global player in pharmaceutical [...]

Pages